Video+

Korey Hood outlines some psychologic issues that should be addressed to optimize the uptake of diabetes technologies by adolescents (4:46).

Simon Heller outlines some straightforward tactics for assessing people’s risk for hypoglycemia during routine consultations (2:49).

Kath Barnard talks about why is it important to feature psychologic research and patient-reported outcomes at a diabetes technology conference (1:44).

Engineer and endocrinologist Rayhan Lal, from Stanford University in California, USA, explains the phenomenon of DIY closed-loop insulin delivery and what to do if a patient wants to adopt it.

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.

Amrit Lamba considers the rather mixed results of the PREVIEW project, and what they mean for primary care (3:40).

Lori Berard comments on the results of a study that identifies barriers to basal insulin initiation and factors associated with insulin interruption among patients with type 2 diabetes (2:14).

John Wilding discusses the unexpected results of HARMONY, the albiglutide cardiovascular outcomes study (2:43).

Nurse consultant and diabetes educator Lori Berard discusses the consensus report on managing hyperglycemia in people with type 2 diabetes (2:42).

Amrit Lamba gives his view of what the updated ADA/EASD hyperglycemia guidelines mean for primary care practitioners (6:08).

Hyperglycemia management in type 2 diabetes guidelines author Melanie Davies discusses the key updates in the 2018 edition, the evidence behind them, and the experience of being part of a trans-Atlantic consensus group (5:13).

Professor Miles Fisher talks about the how the UKPDS shook up the treatment landscape for people with diabetes and set the stage for modern clinical research (3:13).

John Wilding has been sitting on the fence about the prospects for SGLT2 inhibitors in type 1 diabetes. Is he swayed by the latest findings? (3:43)

Lori Berard reflects on the latest evidence for SGLT2 inhibition as an adjunct to insulin in patients with type 1 diabetes (1:52).

Kevin Fernando discusses the implications of the VADT 15-year findings for managing older patients with diabetes in primary care (2:22).

Read the accompanying news story here

Dana Dabelea discusses the RISE investigators’ findings about the physiology of type 2 diabetes in children and the effects of medication on its progression (7:38).

Read the accompanying news story here

Medha Munshi comments on the VADT trial, showing that the cardioprotective effect of intensive glycemic control in patients with type 2 diabetes disappears after 15 years (3:04).

Read the accompanying news story here

John Wilding explains how the latest update of the nutrition guidelines will help clinicians working with patients with obesity (1:53).

Registered Dietitian Pamela Dyson explains why the latest update of the nutrition guidelines is an important departure from previous versions (0:45).